Neurogene to Present NGN-401 Rett Syndrome Gene Therapy Data at ESGCT Congress

• Neurogene will present NGN-401 Rett syndrome gene therapy data at ESGCT’s annual congress, Oct. 27-30, 2026, in Hamburg, Germany.
• An Oct. 29 presentation will examine gene expression timing alongside early treatment-response observations from the Phase 1/2 trial.
• Oct. 28 presentations will cover preclinical comparisons of gene regulation approaches, including its EXACT technology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261020171862) on October 20, 2026, and is solely responsible for the information contained therein.